Regulation of Abro1/KIAA0157 during myocardial infarction and cell death reveals a novel cardioprotective mechanism for Lys63-specific deubiquitination

Journal of Molecular and Cellular Cardiology

Volumn 50, Issue 4, 2011, Pages 652-661

  Cilenti, Lucia ^a   Balakrishnan, Meenakshi P ^a   Wang, Xiao Liang ^b   Ambivero, Camilla ^a   Sterlicchi, Martin ^a   del Monte, Federica ^c   Ma, Xin L ^b   Zervos, Antonis S ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Abro1; BRISC enzyme; Coronary Artery Disease; K63 linked deubiquitination; Myocardial Ischemia Reperfusion

Indexed keywords

ABRO1 PROTEIN; DEUBIQUITINATING ENZYME; ENZYME; LYSINE; POLYPEPTIDE; POLYUBIQUITIN; SCAFFOLD PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL DAMAGE; CELL DEATH; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEUBIQUITINATION; DISEASE COURSE; ENZYME ACTIVITY; ENZYME SUBUNIT; HEART; HEART DISEASE; HEART INFARCTION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HUMAN CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MODIFICATION; PROTEIN TARGETING; RAT; REPERFUSION INJURY; UPREGULATION;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE; CELLS, CULTURED; CORONARY ARTERY DISEASE; DNA-BINDING PROTEINS; HELA CELLS; HUMANS; HYDROGEN PEROXIDE; MICE; MICE, INBRED C57BL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; NUCLEAR MATRIX-ASSOCIATED PROTEINS; NUCLEAR PROTEINS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 79952070183     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2010.12.015     Document Type: Article

References (46)

1. Chen Z.J., Sun L.J. Nonproteolytic functions of ubiquitin in cell signaling. Mol Cell 2009, 33(3):275-286.
2. Kaiser P., Huang L. Global approaches to understanding ubiquitination. Genome Biol 2005, 6(10):233.
3. Reyes-Turcu F.E., Wilkinson K.D. Polyubiquitin binding and disassembly by deubiquitinating enzymes. Chem Rev 2009, 109(4):1495-1508.
4. Reyes-Turcu F.E., Ventii K.H., Wilkinson K.D. Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 2009, 78:363-397.
5. Ikeda F., Dikic I. Atypical ubiquitin chains: new molecular signals. 'Protein Modifications: Beyond the Usual Suspects' review series. EMBO Rep 2008, 9((6):536-542.
6. Ventii K.H., Wilkinson K.D. Protein partners of deubiquitinating enzymes. Biochem J 2008, 414(2):161-175.
7. Daniel J.A., Grant P.A. Multi-tasking on chromatin with the SAGA coactivator complexes. Mutat Res 2007, 618(1-2):135-148.
8. Kennedy R.D., D'Andrea A.D. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev 2005, 19(24):2925-2940.
9. Song L., Rape M. Reverse the curse-the role of deubiquitination in cell cycle control. Curr Opin Cell Biol 2008, 20(2):156-163.
10. Komada M. Controlling receptor downregulation by ubiquitination and deubiquitination. Curr Drug Discov Technol 2008, 5(1):78-84.
11. Shan J., Brooks C., Kon N., Li M., Gu W. Dissecting roles of ubiquitination in the p53 pathway. Ernst Schering Found Symp Proc 2008, 1:127-136.
12. Li H.H., Willis M.S., Lockyer P., Miller N., McDonough H., et al. Atrogin-1 inhibits Akt-dependent cardiac hypertrophy in mice via ubiquitin-dependent coactivation of Forkhead proteins. J Clin Invest 2007, 117(11):3211-3223.
13. Patterson C., Ike C., Willis PWt, Stouffer G.A., Willis M.S. The bitter end: the ubiquitin-proteasome system and cardiac dysfunction. Circulation 2007, 115(11):1456-1463.
14. Rodriguez J.E., Schisler J.C., Patterson C., Willis M.S. Seek and destroy: the ubiquitin-proteasome system in cardiac disease. Curr Hypertens Rep 2009, 11(6):396-405.
15. Mearini G., Schlossarek S., Willis M.S., Carrier L. The ubiquitin-proteasome system in cardiac dysfunction. Biochim Biophys Acta 2008, 1782(12):749-763.
16. Willis M.S., Patterson C. Into the heart: the emerging role of the ubiquitin-proteasome system. J Mol Cell Cardiol 2006, 41(4):567-579.
17. Carrier L., Schlossarek S., Willis M.S., Eschenhagen T. The ubiquitin-proteasome system and nonsense-mediated mRNA decay in hypertrophic cardiomyopathy. Cardiovasc Res 2010, 85(2):330-338.
18. Weekes J., Morrison K., Mullen A., Wait R., Barton P., et al. Hyperubiquitination of proteins in dilated cardiomyopathy. Proteomics 2003, 3(2):208-216.
19. Gong B., Leznik E. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect 2007, 20(6):365-370.
20. Jensen D.E., Proctor M., Marquis S.T., Gardner H.P., Ha S.I., et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998, 16(9):1097-1112.
21. Nijman S.M., Huang T.T., Dirac A.M., Brummelkamp T.R., Kerkhoven R.M., et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 2005, 17(3):331-339.
22. Balakrishnan M.P., Cilenti L., Mashak Z., Popat P., Alnemri E.S., et al. THAP5 is a human cardiac-specific inhibitor of cell cycle that is cleaved by the proapoptotic Omi/HtrA2 protease during cell death. Am J Physiol Heart Circ Physiol 2009, 297(2):H643-H653.
23. Cooper E.M., Cutcliffe C., Kristiansen T.Z., Pandey A., Pickart C.M., et al. K63-specific deubiquitination by two JAMM/MPN+complexes: BRISC-associated Brcc36 and proteasomal Poh1. EMBO J 2009, 28(6):621-631.
24. Cooper E.M., Boeke J.D., Cohen R.E. Specificity of the BRISC deubiquitinating enzyme is not due to selective binding to K63-linked polyubiquitin. J Biol Chem 2009, 285(14):10344-10352.
25. Wang B., Hurov K., Hofmann K., Elledge S.J. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev 2009, 23(6):729-739.
26. Wang B., Matsuoka S., Ballif B.A., Zhang D., Smogorzewska A., et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007, 316(5828):1194-1198.
27. Patterson-Fortin J., Shao G., Bretscher H., Messick T.E., Greenberg R.A. Differential regulation of JAMM domain deubiquitinating enzyme activity within the RAP80 complex. J Biol Chem 2010, 285(40):30971-30981.
28. Feng L., Wang J., Chen J. The Lys63-specific deubiquitinating enzyme BRCC36 is regulated by two scaffold proteins localizing in different subcellular compartments. J Biol Chem 2010, 285(40):30982-30988.
29. Cilenti L., Soundarapandian M.M., Kyriazis G.A., Stratico V., Singh S., et al. Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. J Biol Chem 2004, 279(48):50295-50301.
30. Faccio L., Fusco C., Viel A., Zervos A.S. Tissue-specific splicing of Omi stress-regulated endoprotease leads to an inactive protease with a modified PDZ motif. Genomics 2000, 68(3):343-347.
31. Hescheler J., Meyer R., Plant S., Krautwurst D., Rosenthal W., et al. Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart. Circ Res 1991, 69(6):1476-1486.
32. Faccio L., Fusco C., Chen A., Martinotti S., Bonventre J.V., et al. Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J Biol Chem 2000, 275(4):2581-2588.
33. del Monte F., Kaumann A.J., Poole-Wilson P.A., Wynne D.G., Pepper J., et al. Coexistence of functioning beta 1- and beta 2-adrenoceptors in single myocytes from human ventricle. Circulation 1993, 88(3):854-863.
34. del Monte F., O'Gara P., Poole-Wilson P.A., Yacoub M., Harding S.E. Cell geometry and contractile abnormalities of myocytes from failing human left ventricle. Cardiovasc Res 1995, 30(2):281-290.
35. del Monte F., Harding S.E., Dec G.W., Gwathmey J.K., Hajjar R.J. Targeting phospholamban by gene transfer in human heart failure. Circulation 2002, 105(8):904-907.
36. Natarajan A.R., Rong Q., Katchman A.N., Ebert S.N. Intrinsic cardiac catecholamines help maintain beating activity in neonatal rat cardiomyocyte cultures. Pediatr Res 2004, 56(3):411-417.
37. De Windt L.J., Lim H.W., Taigen T., Wencker D., Condorelli G., et al. Calcineurin-mediated hypertrophy protects cardiomyocytes from apoptosis in vitro and in vivo: an apoptosis-independent model of dilated heart failure. Circ Res 2000, 86(3):255-263.
38. Sreejit P., Kumar S., Verma R.S. An improved protocol for primary culture of cardiomyocyte from neonatal mice. In Vitro Cell Dev Biol Anim 2008, 44(3-4):45-50.
39. Song G., Campos B., Wagoner L.E., Dedman J.R., Walsh R.A. Altered cardiac annexin mRNA and protein levels in the left ventricle of patients with end-stage heart failure. J Mol Cell Cardiol 1998, 30(3):443-451.
40. Wang Y., Lau W.B., Gao E., Tao L., Yuan Y., et al. Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia/reperfusion injury. Am J Physiol Endocrinol Metab 2010, 298(3):E663-E670.
41. Tao L., Wang Y., Gao E., Zhang H., Yuan Y., et al. Adiponectin. An indispensable molecule in rosiglitazone cardioprotection following myocardial infarction. Circ Res 2010, 106(2). 409-1.
42. 2-induced apoptosis. FEBS J 2008, 275(12):3136-3144.
43. 2-induced apoptosis through AKT signaling. Biochem Biophys Res Commun 2007, 359(3):685-690.
44. Sobhian B., Shao G., Lilli D.R., Culhane A.C., Moreau L.A., et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007, 316(5828):1198-1202.
45. Kim H., Chen J., Yu X. Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response. Science 2007, 316(5828):1202-1205.
46. Baer R., Ludwig T. The BRCA1/BARD1 heterodimer, a tumor suppressor complex with ubiquitin E3 ligase activity. Curr Opin Genet Dev 2002, 12(1):86-91.